成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告全文 成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告全文 财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：成都市贝瑞和康基因技术股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 359,908,471.56 | 383,071,864.35 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 10,479,041.92 | 17,032,640.72 | | 衍生金融资产 | | | | 应收票据 | 6,414,646.08 | 2,587,200.00 | | 应收账款 | 659,878,630.79 | 692,131,312.99 | | 应收款项融资 | | ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-046 成都市贝瑞和康基因技术股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保审批情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因""公司"） 于 2025 年 8 月 20 日召开第十届董事会第十六次会议审议通过了《关于为全资 子公司提供担保的议案》。公司之全资子公司杭州贝瑞和康基因诊断技术有限 公司（以下简称"杭州贝瑞"）向杭州联合农村商业银行股份有限公司高沙支 行（以下简称"杭州联合银行高沙支行"）申请综合授信 4,000 万元，授信期 限 1 年。公司同意为杭州贝瑞使用上述授信所形成的债务提供连带责任保证担 保。具体内容详见公司于 2025 年 8 月 21 日在巨潮资讯网上披露的《关于为全 资子公司提供担保的公告》（公告编号：2025-042）。 5、法定代表人：高扬 6、注册资本：11,500 万元人民币 7、注册地点：浙江省杭州经济技术开发区白杨街道 6 号大街 260 号 9 幢,16 幢一层、二层 8、经营 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥447,434,341.07, representing a decrease of 18.91% compared to ¥551,776,302.07 in the same period last year[18]. - The net loss attributable to shareholders for the first half of 2025 was ¥27,242,543.15, a decline of 394.11% from a profit of ¥9,262,843.84 in the previous year[18]. - The net cash flow from operating activities was negative at ¥31,902,432.23, a decrease of 341.76% compared to a positive cash flow of ¥13,195,640.30 in the same period last year[18]. - Basic and diluted earnings per share for the first half of 2025 were both -¥0.0771, down 394.27% from ¥0.0262 in the previous year[18]. - The company achieved revenue of ¥447,434,341.07 in the first half of 2025, with a net profit attributable to shareholders of -¥27,242,543.15[47]. - The company's revenue for the reporting period was ¥447,434,341.07, a decrease of 18.91% compared to ¥551,776,302.07 in the same period last year[60]. - The company reported a significant increase in credit impairment losses by 80.08% to -¥15,756,033.26, attributed to lower collection rates from major clients[66]. - The total comprehensive income decreased from ¥12,977,621.95 to a loss of ¥29,360,673.05, indicating a significant downturn[152]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,422,090,357.68, an increase of 1.57% from ¥2,384,723,994.06 at the end of the previous year[18]. - The net assets attributable to shareholders decreased by 2.11% to ¥1,643,967,241.41 from ¥1,679,476,362.94 at the end of the previous year[18]. - Total liabilities rose to ¥741,261,590.68, up from ¥669,562,176.39, marking an increase of around 10.70%[144]. - Owner's equity totaled ¥1,680,828,767.00, down from ¥1,715,161,817.67, showing a decrease of about 2.00%[144]. - The company reported a total current assets balance of ¥1,383,056,439.13 as of June 30, 2025, down from ¥1,439,086,278.92 at the beginning of the period, representing a decrease of approximately 3.9%[142]. Cash Flow - Operating cash flow for the first half of 2025 was negative at -¥31,902,432.23, compared to a positive 13,195,640.30 in the same period of 2024, indicating a decline in operational efficiency[157]. - Cash inflow from financing activities increased to 149,260,233.43 CNY in 2025 from 99,996,255.68 CNY in 2024, showing a growth of approximately 49%[158]. - The company reported a total cash outflow of -¥19,284,848.07 for the first half of 2025, an improvement compared to -¥49,888,963.87 in the same period of 2024[158]. Research and Development - The company is actively involved in research and development of new products and technologies to enhance its genetic testing capabilities[25]. - Research and development expenses increased from ¥39,768,904.04 to ¥52,519,317.48, an increase of approximately 32%[151]. - The company aims to increase its R&D expenditure by 17.51% in the upcoming fiscal year to drive innovation[172]. Market Strategy and Expansion - The company plans to expand its market presence by leveraging its proprietary sequencing platforms and comprehensive service offerings[25]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[165]. - The company plans to expand its market presence by entering two new regions in the next quarter[165]. Product Offerings - The company focuses on high-throughput sequencing technology and third-generation HiFi sequencing technology for genetic testing services and related equipment, reagents, and software sales[25]. - The company offers a comprehensive range of genetic testing services, including over 1,700 single-gene hereditary diseases and various prenatal and newborn screening tests[26]. - The company has established a comprehensive range of sequencing analysis services, utilizing leading gene sequencing platforms such as Illumina NovaSeq X Plus and PacBio Revio[30]. Risks and Challenges - The company highlighted risks and challenges in its future operations, which are detailed in the management discussion section[4]. - The company faces risks from intensified market competition and declining service prices, which could impact future performance[83]. - The company is at risk of technological and product innovation lag, which may affect market share and profitability[84]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[92]. - The total number of ordinary shareholders at the end of the reporting period was 68,183[131]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., held a 12.45% stake, amounting to 44,002,000 shares, which were pledged[131].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][4]. Core Insights - The company focuses on reproductive health and genetic disease testing, providing a comprehensive solution of "products + services" and is a leading player in the domestic genetic testing field [1][15]. - The market for life science sequencing solutions in China is expected to grow at a compound annual growth rate (CAGR) of 14.9% from 2018 to 2023, reaching 138.8 billion yuan by 2033, indicating potential for the company's continued market penetration [1]. - The company is leveraging its data and technology to build competitive barriers in the AI healthcare industry, with the AI medical market projected to reach 11.43 billion yuan by 2025 and 28.61 billion yuan by 2027 [2]. Summary by Sections Company Overview and Business Layout - The company, established in 2010 and listed in 2017, began with non-invasive prenatal testing (NIPT) and has expanded into genetic disease testing and research services [15]. - It utilizes high-throughput sequencing and third-generation HiFi sequencing technologies to provide genetic testing services and related equipment, reagents, and software [15]. Industry Development and Core Business - The company’s core business includes high-throughput sequencing technology and third-generation sequencing services, focusing on reproductive health and genetic disease testing [40]. - The company has established a comprehensive service model for hospitals and third-party laboratories, integrating advanced sequencing technology with AI applications [40]. Financial Performance and Forecast - The company’s revenue is projected to be 1.05 billion yuan in 2025, with a gradual increase to 1.42 billion yuan by 2027, while net profit is expected to improve from a loss of 140 million yuan in 2025 to a profit of 400 million yuan in 2027 [3][4]. - The company’s gross margin has shown an upward trend, increasing from 42.72% in 2022 to 46.86% in 2024, driven by a higher proportion of reagent sales [29]. AI Medical Sector - The company is positioned to capitalize on the AI medical sector, with its GENOisi™ intelligent model facilitating a smart data management and clinical decision-making process [2][20]. - The AI medical market is rapidly expanding, supported by favorable domestic policies, and the company aims to leverage its extensive clinical data and self-developed algorithms for commercial applications [2].

Group 1 - The stock price of Berry Genomics closed at 15.94 yuan on August 26, 2025, down 4.03% from the previous trading day, with a trading volume of 977 million yuan [1] - Berry Genomics operates in the medical device, AI pharmaceutical, and assisted reproduction sectors, focusing on the research and application of gene sequencing technology [2] - The company's subsidiary, Hangzhou Berry Health and Technology Co., Ltd., recently received a medical device registration certificate from the National Medical Products Administration for its NovaSeq6000Dx-CN-BG gene sequencer, which meets various gene testing needs for the prevention of birth defects [2] Group 2 - On August 26, 2025, the main capital outflow for Berry Genomics was 193 million yuan, accounting for 3.71% of its circulating market value [2] - Over the past five days, the main capital inflow was 261 million yuan, representing 5.01% of its circulating market value [2]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-044 成都市贝瑞和康基因技术股份有限公司 关于全资子公司基因测序仪获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）全资子公司杭 州贝瑞和康基因诊断技术有限公司的NovaSeq™ 6000Dx-CN-BG基因测序仪于近日 正式获得国家药品监督管理局（NMPA）颁发的医疗器械注册证（注册证编号：国 械注准20253221734）。现将具体情况公告如下： | 产品名称 | 基因测序仪 | | --- | --- | | 注册人名称 | 杭州贝瑞和康基因诊断技术有限公司 | | 注册证编号 | 国械注准20253221734 | | 型号及规格 | NovaSeqTM 6000Dx-CN-BG | | 有效期 | 2025年8月25日至2030年8月24日 | | 结构及组成 | 产品功能上由移液模块，光学模块，数据处理模块和触屏显示控制部分组成。 结构上由一个触摸显示器，一个状态显示区，一个测序芯片室和一个试剂存 | | ...

Core Viewpoint - Berry Genomics (000710) announced that its wholly-owned subsidiary, Hangzhou Berry Genomics and Health Technology Co., Ltd., has recently received a medical device registration certificate from the National Medical Products Administration for its NovaSeq6000Dx-CN-BG gene sequencer, which can meet various genetic testing needs for the three-level prevention of birth defects [1] Company Summary - The NovaSeq6000Dx-CN-BG high-throughput sequencer is designed to fulfill the genetic testing requirements related to the prevention of birth defects [1]

Core Viewpoint - Berry Genomics' subsidiary has received a medical device registration certificate for its NovaSeq™6000Dx-CN-BG gene sequencer, indicating a significant advancement in the company's product offerings in the field of DNA sequencing [1]. Company Summary - Berry Genomics announced that its wholly-owned subsidiary, Hangzhou Berry Genomics Technology Co., Ltd., has obtained a medical device registration certificate from the National Medical Products Administration for the NovaSeq™6000Dx-CN-BG gene sequencer [1]. - The NovaSeq™6000Dx-CN-BG utilizes reversible terminator sequencing technology, which is clinically applied for human deoxyribonucleic acid (DNA) sequencing [1].

Market Overview - On August 26, the AI medical sector experienced a slight decline of 0.01%, with Bei Rui Gene leading the losses [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Notable gainers in the AI medical sector included: - Saily Medical (603716) with a closing price of 36.40, up 4.99% and a trading volume of 707,500 shares, totaling 2.592 billion yuan [1] - Sichuang Medical (300078) closed at 3.80, up 2.98% with a trading volume of 666,200 shares, totaling 250 million yuan [1] - Jiahe Meikang (688246) closed at 38.21, up 2.00% with a trading volume of 56,600 shares, totaling 215 million yuan [1] - Major decliners included: - Bei Rui Gene (000710) closed at 15.94, down 4.03% with a trading volume of 609,700 shares, totaling 977 million yuan [2] - Yao Shi Technology (300725) closed at 45.18, down 3.91% with a trading volume of 165,300 shares, totaling 756 million yuan [2] - Anbiping (688393) closed at 31.66, down 3.21% with a trading volume of 40,200 shares, totaling 129 million yuan [2] Capital Flow - The AI medical sector saw a net outflow of 707 million yuan from institutional investors, while retail investors experienced a net inflow of 697 million yuan [2] - The table of capital flow indicates that: - Wei Ning Health (300253) had a net inflow of 75.39 million yuan from institutional investors [3] - Zhejiang Data Culture (600633) had a net inflow of 67.70 million yuan from institutional investors [3] - Huada Gene (300676) had a net inflow of 23.14 million yuan from institutional investors [3]

Core Viewpoint - The collaboration between Chengdu Berry Genomics Co., Ltd. and its partners aims to drive innovation in medical technology and industry upgrades through digital assetization, exploring RWA applications to reshape the global gene diagnostic asset value chain and maximize asset value [1][2]. Group 1: Company Overview - Berry Genomics focuses on technological innovation to advance precision medicine, utilizing high-throughput sequencing technology to create solutions across various fields, including reproductive health and genetic disease testing [2]. - The company has pioneered the clinical transformation of third-generation HiFi sequencing technology and has successfully launched multiple products, establishing a strong technological moat [2]. Group 2: Collaboration Details - The partners plan to use the stable revenue from Berry Genomics' third-generation HiFi sequencing production line and the technical service income from the GENOisi™ intelligent system as underlying assets for digital rights exploration and RWA tokenization [4]. - The project aims to quantify the value of the GENOisi™ intelligent system as a new type of digital asset, accelerating the integration of technology and capital, thereby injecting new momentum into the sustainable development of precision medicine [4]. Group 3: Future Directions - This collaboration represents a critical step in the digitalization of healthcare assets, standardizing data rights in the medical health sector and enhancing the quantification and circulation of new digital assets like AI intelligent systems [5]. - The company intends to deepen technical and resource collaboration with partners, actively exploring more digital paths for medical assets, contributing to the popularization of precision medicine, data value extraction, and the upgrade of the global healthcare ecosystem [5].